BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
These 2 moon rovers used cameras and lasers to hunt for simulated water ice — and one looks like WALL-E - 2Different Film Classification: What's Your Go-To for Amusement
- 3AstraZeneca to invest $2 billion as part of US manufacturing push
- 410 Fundamental Tips and Deceives to Lift Your Cell phone's Exhibition
- 5Benedict Cumberbatch takes on something even Sherlock can’t solve: male grief
- Putin says Russian forces will seize capital of Zaporizhzhya
- NAFFIC and Aware to Launch First China-Europe Digital Product Passport
- European Travel Objections for 2024
- If everyone on Earth sat in the ocean at once, how much would sea level rise?
- ADHD drugs work, but not the way experts thought
- IDF strikes terror infrastructure across Iran, attack reported on Kashan airport
- Ukraine to get up to 100 French-made Rafale fighter jets
- Watch SpaceX launch 119 payloads to orbit from California early on March 30
- Scientists discover black hole flare with the light of 10 trillion suns
